

alk(en/yn)yxycarbonyl or C₁₋₆-alk(en/yn)ylsulfonyl; or -NR¹³R¹⁴ wherein R¹³ and R¹⁴ are each independently hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl or aryl, or R¹³ and R¹⁴ together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and N;

R⁵ is aryl or monocyclic heteroaryl, optionally substituted with a halogen, cyano, nitro, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yoxy, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(en/yn)yxycarbonyl, C₁₋₆-alk(en/yn)ylsulfonyl or -NR¹⁵R¹⁶ wherein R¹⁵ and R¹⁶ are each independently hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl or aryl, or R¹⁵ and R¹⁶ together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and N;

R⁶ is H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is C₁₋₆-alk(en/yn)yoxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² are each independently H or C₁₋₆ alkyl;

R⁷ and R⁸ are each independently H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl;

R⁹ and R^{9'} are each independently H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁶ and R⁸ together with the atoms to which they are attached and the intervening carbon atom form a saturated 3-7 membered heterocyclic ring, and R⁷ is H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R⁹ and R^{9'} are each independently H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁷ and R⁸ together with the atoms to which they are attached form a saturated 3-7 membered heterocyclic ring, and R⁶ is H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is C₁₋₆-alk(en/yn)yoxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² are each independently H or C₁₋₆ alkyl, and R⁹ and R^{9'} are each independently H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁸ and R⁹ together with the atoms to which they are attached and the intervening carbon atom form a saturated 3-7 membered heterocyclic ring, and R⁶ is H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is C₁₋₆-alk(en/yn)yoxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² are each independently H or C₁₋₆ alkyl, and R⁷ is H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R^{9'} is H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl;

R¹⁰ is H, C₁₋₆-alk(en/yn)yl, aryl, aryl-C₁₋₆-alk(en/yn)yl, wherein aryl is optionally substituted with a halogen, CF₃, OCF₃, CN, NO₂ or C₁₋₆-alk(en/yn)yl, or an alkali metal;

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound of claim 1 wherein X is O or CH₂.
3. (Previously presented) The compound of claim 1 wherein Y is O.
4. (Previously presented) The compound of claim 1 wherein Y is S.
5. (Previously presented) The compound of claim 1 wherein R¹ is hydrogen, C₁₋₆-alkyl, halogen, phenyl, or phenyl substituted with one or two substituents selected from C₁₋₆-alkyl and C₁₋₆-alkoxy.

6. (Previously presented) The compound of claim 1 wherein R^2 is hydrogen; cyano; C_{1-6} -alkyl; halogen; phenyl; phenyl substituted with one or two substituents selected from cyano, C_{1-6} -alkyl, C_{1-6} -alkoxy, and C_{1-6} -alkylsulfonyl; $-NR^{13}R^{14}$ wherein R^{13} and R^{14} together with the nitrogen atom to which they are attached form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S and N; or monocyclic heteroaryl.
7. (Previously presented). The compound of claim 1 wherein R^3 is hydrogen; C_{1-6} -alkyl; halogen; phenyl; phenyl substituted with one or two substituents selected from cyano, C_{1-6} -alkyl, and C_{1-6} -alkoxy; or monocyclic heteroaryl.
8. (Previously presented) The compound of claim 1 wherein R^4 is hydrogen, C_{1-6} -alkyl, halogen, phenyl or phenyl substituted with one or two substituents selected from C_{1-6} -alkyl and C_{1-6} -alkoxy.
9. (Previously presented) The compound of claim 1 wherein R^5 is phenyl, optionally substituted with a halogen, C_{1-6} -alkyl, C_{1-6} -alkyloxy, C_{1-6} -alkylsulfonyl, or halo- C_{1-6} -alkyl.
10. (Previously presented) The compound of claim 1 wherein R^6 is H or C_{1-6} -alkyl.
11. (Previously presented) The compound of claim 1 wherein R^7 is H or C_{1-6} -alkyl.
12. (Previously presented) The compound of claim 1 wherein R^8 is H, C_{1-6} -alkyl or C_{3-8} -cycloalkyl.
13. (Previously presented) The compound of claim 1 wherein R^9 and $R^{9'}$ are each independently H or C_{1-6} -alkyl.
14. (Previously presented) The compound of claim 1 wherein R^{10} is H.

15. (Previously presented) The compound of claim 1 wherein R⁶ and R⁸ together with the atoms to which they are attached and the intervening carbon atom form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C₁₋₆-alkyl, and R⁷ is H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R⁹ and R^{9'} are each independently H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl.

16. (Previously presented) The compound of claim 1 wherein R⁷ and R⁸ together with the atoms to which they are attached form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C₁₋₆-alkyl, and R⁶ is H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is C₁₋₆-alk(en/yn)yoxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² are each independently H or C₁₋₆ alkyl, and R⁹ and R^{9'} are independently H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl.

17. (Previously presented) The compound of claim 1 wherein R⁸ and R⁹ together with the atoms to which they are attached and the intervening carbon atom form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C₁₋₆-alkyl, and R⁶ is H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yoxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is C₁₋₆-alk(en/yn)yoxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² are each independently H or C₁₋₆ alkyl, and R⁷ is H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R^{9'} is H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl.

18. (Currently amended) The compound of claim 1 selected from the group consisting of:
(S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
1-{2(R/S)-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
1-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
1-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
1-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
1-{2(R/S)-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
~~(({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid~~ ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]methyl}-piperidin-1-yl}-acetic acid,
({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
{4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
(N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
(N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
(S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
(N-2-propyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
({2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
2-{3-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid
({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
{2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenoxy-methyl]-piperidin-1-yl}-acetic acid,
({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
(N-Methyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-[3(R)-(2-(4-methylphenyl)-sulfanyl-phenoxy)-pyrrolidin-1-yl]-propionic acid,
{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,
2-{3(R)-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
2-{3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy-methyl]-propyl}-N-ethyl-amino)-acetic acid,
~~({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid~~ ({1-[2-
(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-amino)-acetic
acid,
({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[1-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,
~~({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl-2-yl}-N-ethyl-amino)-~~
~~acetic acid~~ ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-
amino)-acetic acid,
({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid,
~~(S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid~~ (S)-
({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,
~~(S)-({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid~~ (S)-
({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,
({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

(~~{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]methyl}-propyl~~)-N-methyl-amino)-acetic acid,
(~~{1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]methyl}-propyl~~)-N-ethyl-amino)-acetic acid,
(N-Ethyl-~~{1-[2-(3-fluoro-phenylsulfanyl)-phenoxy]methyl}-propyl~~)-amino)-acetic acid,
(R)-(~~{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-1-methyl-ethyl}~~)-N-ethyl-amino)-acetic acid,
(S)-(~~{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino}~~)-acetic acid (S)-(~~2-{1-[2-(4-Chloro-phenoxy)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid,
(R)-(~~{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl-N-methyl-amino}~~)-acetic acid (R)-(~~2-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid,
(~~{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}~~)-N-methyl-amino)-acetic acid,
(~~{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}~~)-N-ethyl-amino)-acetic acid,
(~~{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}~~)-N-methyl-amino)-acetic acid,
(~~{3-methyl-1-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}~~)-N-ethyl-amino)-acetic acid,
(~~{1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}~~)-N-methyl-amino)-acetic acid,
(S)-(~~1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid (S)-(~~{1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid,
(S)-(~~2-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl-N-methyl-amino}~~)-acetic acid (S)-(~~{1-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid,
(~~{1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}~~)-N-ethyl-amino)-acetic acid,
(S)-(~~{1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-methyl-amino)-acetic acid,
(~~{1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}~~)-N-methyl-amino)-acetic acid (~~{1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}~~)-N-methyl-amino)-acetic acid,
(~~{1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl}~~)-N-ethyl-amino)-acetic acid (~~{1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-propan-2-yl}~~)-N-ethyl-amino)-acetic acid,
(~~{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-1-yl}~~)-N-ethyl-amino)-acetic acid,
(~~{2-[2-(4-methoxy-phenylsulfanyl)-phenoxy]-propan-1-yl}~~)-N-Cyclohexyl-amino)-acetic acid,
(~~{2-[2-(4-methylsulfanyl)-phenoxy]-propan-1-yl}~~)-N-cyclohexyl-amino)-acetic acid (~~{2-[2-(4-methyl-phenylsulfanyl)-phenoxy]-propan-1-yl}~~)-N-cyclohexyl-amino)-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-cyclohexyl-amino)-acetic acid,
(S)-1-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrrolidine-2-carboxylic acid,
(S)-2-({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-propionic acid,
({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-acetic acid,
(S)-1-{2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
~~(S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid~~
(S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[4-Cyano-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid
(S)-1-{2-[5-Chloro-2-phenylsulfanyl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,
(S)-{2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic
acid,
(S)-1-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-5-thiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-
2(S)-carboxylic acid,
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpholin-4-yl-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid, and
(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-1-yl-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid,
or a pharmaceutically acceptable salt thereof.

19. (Previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent.

20. (Canceled)

21. (Currently amended) A method for the treatment of a disease or disorder selected from the group consisting of post-traumatic stress disorder, ~~psychoses~~ psychosis, a condition ~~conditions~~ where the cognitive processes are diminished, and a convulsive disorder ~~disorders~~, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.

22. (Previously presented) The method of claim 21, wherein said method is for the treatment of the positive or negative symptoms of schizophrenia.

23. (Previously presented) The method of claim 22, wherein said method is for the treatment of both the positive and negative symptoms of schizophrenia.

24. (Previously presented) The method of claim 21, wherein said method is for the treatment of Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, or diseases wherein the brain is damaged by inner or outer influence.

25. (Previously presented) The method of claim 24, wherein said method is for the treatment of brain damage due to trauma to the head or stroke.

26. (Previously presented) The method of claim 21, wherein said method is for the treatment of epilepsy, spasticity or myoclonus.

27. (Previously presented) The method of claim 21 wherein said subject is a human.

28. (Previously presented) A pharmaceutical composition comprising a compound according to claim 18 and a pharmaceutically acceptable carrier or diluent.